Andere Sprachen Lisata Therapeutics, Inc.

Aktien

A3DWGC

US1280583022

LSTA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 17.04.2024			% 5 Tage	% 1. Jan.
2.78 ^USD	-2.11%		-8.55%	+1.83%

09.04.	Lisata Therapeutics gibt bekannt, dass die U.S. Food and Drug Administration (FDA) LSTA1 den Status eines Arzneimittels für seltene Leiden (Orphan Drug Designation) für die Behandlung von Osteosarkomen erteilt hat	CI
21.03.	Sektor-Update: Aktien des Gesundheitswesens im späten Nachmittagshandel höher	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	09.04.
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	09.04.
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events	03.04.
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	21.03.
Sector Update: Health Care Stocks Higher in Afternoon Trading	21.03.
Lisata Therapeutics Says FDA Grants Rare Pediatric Disease Designation to Osteosarcoma Drug	21.03.
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma	21.03.
Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ	04.03.
Lisata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.02.
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update	29.02.
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time	22.02.
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time	22.02.
Lisata Therapeutics to Present at BIO CEO & Investor Conference	20.02.
Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico	18.01.
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme	17.01.
Lisata Therapeutics, Inc. Announces First Patient Treated in the Phase 2A Trial of Lsta1 in Patients with Glioblastoma Multiforme	17.01.
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy	04.01.
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy	04.01.
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma	12.12.
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma	12.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Lisata Therapeutics, Inc.

Aktien

A3DWGC

US1280583022

LSTA

Andere Sprachen

Filter